**6. Adipose tissue hormones**

Of note, decrease in VFA and improvement in anthropometric measures were associated to change in secretion of adipose tissue hormones. On Sitagliptin and metformin therapy, a more marked decrease in leptin level by 7.37 ± 5.69 ng/ml (30.47%), р <0.001 was registered, while on metformin monotherapy, leptin level decreased by 1.21 ± 1.34 ng/ml (5.41%), р <0.001.

The study also indicates dynamics of another adipokine-adiponectin that plays a significant role in glucose and lipid metabolism. The initial adiponectin levels in both groups were lower than reference values. After 6 months of therapy, a more marked adiponectin level increase by 1.95 ± 1.53 μg/mL (27.06%), р <0.001 was observed in group I compared to group II, where it is increased by 0.49 ± 0.26 μg/mL, (7.16%), р <0.001. It is known that this hormone secretion is diminished at T2D. The recovery of secretion is accompanied by the improvement in carbohydrate metabolism indicators, lowering of atherogenesis and slowing down of the progression of diabetes vascular events [18].

Adipose tissue hormones dynamics is displayed in **Figure 6**.

Thus, visceral fat area increased on the background of increasing concentration of adiponectin and decreasing leptin content.

**Figure 6.** Dynamics of adipokines.

statistically significant difference between the groups (**Figure 5**). VFA/SFA ratio significantly lowered by 0.18 ± 0.24 (15.26%), p < 0.001 in group I; and by 0.008 ± 0.008 (1.14%), p < 0.001 in

**Figure 5.** Dynamics of visceral and subcutaneous fat by results MRI. VF-visceral fat, SF- subcutaneous fat; \*P between

Of note, decrease in VFA and improvement in anthropometric measures were associated to change in secretion of adipose tissue hormones. On Sitagliptin and metformin therapy, a more marked decrease in leptin level by 7.37 ± 5.69 ng/ml (30.47%), р <0.001 was registered, while on metformin monotherapy, leptin level decreased by 1.21 ± 1.34 ng/ml (5.41%), р <0.001.

The study also indicates dynamics of another adipokine-adiponectin that plays a significant role in glucose and lipid metabolism. The initial adiponectin levels in both groups were lower than reference values. After 6 months of therapy, a more marked adiponectin level increase by 1.95 ± 1.53 μg/mL (27.06%), р <0.001 was observed in group I compared to group II, where it is increased by 0.49 ± 0.26 μg/mL, (7.16%), р <0.001. It is known that this hormone secretion is diminished at T2D. The recovery of secretion is accompanied by the improvement in carbohydrate metabolism indicators, lowering of atherogenesis and slowing down of the progression

Thus, visceral fat area increased on the background of increasing concentration of adiponec-

group II, which is also indicative of more marked lowering of visceral fat in group I.

**6. Adipose tissue hormones**

groups >0.05; \*\*P between groups <0.05.

62 Diabetes and Its Complications

of diabetes vascular events [18].

tin and decreasing leptin content.

Adipose tissue hormones dynamics is displayed in **Figure 6**.
